Revenue and net profit grew year-over-year in Q1 FY25, with EPS rising to ₹154.36. Financials were reviewed and approved without qualifications, and the company continues to operate solely in the pharmaceuticals segment.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.